BIODESIX INC (BDSX)

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets.

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

Biodesix to Participate in Two Upcoming Investor Conferences in November

Biodesix Announces Third Quarter 2023 Results and Highlights

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Biodesix to Participate in Two Upcoming Investor Conferences in September

Thursday 8/24 Insider Buying Report: FTRE, BDSX

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Biodesix Announces Second Quarter 2023 Results and Highlights

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

Biodesix stock gains on PLOS ONE data for lung cancer test

Biodesix (BDSX) added ~10% Wednesday after announcing that the science journal PLOS ONE published data from a study for its lung cancer test Nodify XL2. Read more here.

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Why Shares of CareDx Are Jumping Friday

The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services.

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday!

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting